Poslední aktualizace :
19/11/2024
Infostab
Junginių sąrašas
Sąrašai
Ieškoti suderinamumo
Tableau Incompatibilites
Bibliografija
Mokslinių tyrimų Komandos
valistab
plakatas
Jungtys
rėmėjai
Autorius
Naudojimo instrukcija
Biuletenį
Spironolactone
Cheminė sandara
Bibliografija : Spironolactone
tipas
leidinys
2435
Žurnalas
Allen LV, Jr, Erickson MA,
Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids
Am J Health-Syst Pharm 1996 ; 53: 2304-2309.
2441
Žurnalas
Allen LV, Jr, Erickson MA,
Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids
Am J Health-Syst Pharm 1996 ; 53: 2073-2078.
2489
Žurnalas
Mathur LK, Wickman A
Stability of extemporaneously compounded spironolactone suspensions
Am J Hosp Pharm 1989 ; 46: 2040-2042.
2534
Žurnalas
Nahata MC, Morosco RS, Hipple TF.
Stability of spironolactone in an extemporaneously prepared suspension at two temperatures
Ann Pharmacotherapy 1993 ;27:1198-1199.
2556
Žurnalas
Peterson GM, Meaney MF, Reid CA.
Stability of extemporaneously prepared mixtures of metoprolol and spironolactone.
Aust J Hosp Pharm 1989 ; 19,: 344-346.
2559
Žurnalas
Mc Knight DL.
The formulation of spironolactone solution for paediatric use.
Aust J Hosp Pharm 1993 ; 23: 83.
2854
Žurnalas
Alexander KS, Sundar S, White DB, Dollimore D.
The Formulation Development and Stability of Spironolactone Suspension
Int J Pharm Compound 1997 ; 1, 3: 195-199.
2928
Žurnalas
Salgado AC, Rosa ML, Duarte MA et al.
Stability of spironolactone in an extemporaneously prepared aqueous suspension: the importance of microbiological quality of compounded paediatric formulations.
EJHP Science 2005 ; 11: 68-73.
3810
Žurnalas
Geiger C M, Sorenson B, Whaley P.
Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF.
Int J Pharm Compound 2015 ; 19, 5 : 420-427.
4000
Žurnalas
Graves R, Phan K.V,Bostanian L.A,Mandal T.K, Pramar Y.V.
Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt.
Int J Pharm Compound 2017 ; 21:4 :334-338
4177
Žurnalas
Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A.
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4.
Int J Pharm Compound 2018 ;22,6:516-526
4198
Žurnalas
Uriel M, Gomez-Rincon C, Marro D.
Stability of regularly prescribed oral liquids formulated with SyrSpend® SF.
Pharmazie 2018 73;196-201
4256
Žurnalas
Binson G, Beuzit K, Migeot V, Marco L, Troussier B, Venisse N, Dupuis A.
Preparation and Physicochemical Stability of Liquid Oral Dosage Forms Free of Potentially Harmful Excipient Designed for Pediatric Patients.
Pharmaceutics 2019 ;11,190:
Mentions Légales